LOU064: Clinical Trials

5 trials of LOU064, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 1 terminated. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Recruiting 2, Terminated 1

Follow LOU064: new trials by email Literature Review of LOU064 trials Research Report on LOU064

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
LOU064, Placebo - Papulopustular Rosacea
Phase 2RecruitingNovartis Pharmaceuticals1002026-07-302026-11-10
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
Remibrutinib, Placebo - Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Phase 2RecruitingNovartis Pharmaceuticals442025-05-222026-09-28
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
LOU064, placebo - Allergy, Peanut
Phase 2CompletedNovartis Pharmaceuticals762022-10-122026-06-12
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
LOU064 - Chronic Spontaneous Urticaria
Phase 2CompletedNovartis Pharmaceuticals2292019-10-242024-06-20
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
Remibrutinib, Placebo - Sjögren Syndrome
Phase 2TerminatedNovartis Pharmaceuticals732019-07-122023-01-30

Conditions studied

Chronic Urticaria (2)  ·  Arthritis (1)  ·  Autoimmune Diseases (1)  ·  Chronic Inducible Urticaria (1)  ·  Cold Urticaria (1)  ·  Connective Tissue Diseases (1)  ·  Dry Eye Syndromes (1)  ·  Eye Diseases (1)  ·  Familial dermographism (1)  ·  Food Hypersensitivity (1)  ·  Immune System Diseases (1)  ·  Joint Diseases (1)  ·  Lacrimal Apparatus Diseases (1)  ·  Mouth Diseases (1)  ·  Musculoskeletal Diseases (1)

Sponsors

Novartis Pharmaceuticals (5)

Countries

United States (5)  ·  Spain (4)  ·  Germany (3)  ·  Belgium (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  China (2)  ·  Denmark (2)  ·  France (2)  ·  Hungary (2)  ·  Poland (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)  ·  Czechia (1)

Results publications

PMID 37866460, PMID 37932009

NIH funding

2018 (1), 2019 (1), 2025 (1)